Weineng Feng

2.1k total citations
50 papers, 646 citations indexed

About

Weineng Feng is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Weineng Feng has authored 50 papers receiving a total of 646 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in Weineng Feng's work include Lung Cancer Treatments and Mutations (31 papers), Lung Cancer Research Studies (14 papers) and Colorectal Cancer Treatments and Studies (11 papers). Weineng Feng is often cited by papers focused on Lung Cancer Treatments and Mutations (31 papers), Lung Cancer Research Studies (14 papers) and Colorectal Cancer Treatments and Studies (11 papers). Weineng Feng collaborates with scholars based in China, United States and Macao. Weineng Feng's co-authors include Yanming Deng, Zecheng Chen, Hua Zhang, Jing Wu, Peibin Yue, Xiaolei Zhang, Shumin Ouyang, Peiqing Liu, Jiaye Lu and Ziyou Lin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Cell and Cancer.

In The Last Decade

Weineng Feng

44 papers receiving 642 citations

Peers

Countries citing papers authored by Weineng Feng

Since Specialization

Citations

This map shows the geographic impact of Weineng Feng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weineng Feng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weineng Feng more than expected).

Fields of papers citing papers by Weineng Feng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weineng Feng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weineng Feng. The network helps show where Weineng Feng may publish in the future.

Co-authorship network of co-authors of Weineng Feng

This figure shows the co-authorship network connecting the top 25 collaborators of Weineng Feng. A scholar is included among the top collaborators of Weineng Feng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weineng Feng. Weineng Feng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China 2024 ·Annals of Oncology ·(unknown), Dongqing Lv, Weineng Feng, Shuyu Liu, Puyuan Xing, Yan Yu, Jieyun Yin, Xiubao Ren, (unknown), Guang Han, Yong Zhang, (unknown), (unknown), En Chen, Meng Li	0
2	677P Comparison of performance of MET amplification detection by FISH, NGS and ddPCR in EGFRm advanced NSCLC patients post first-line osimertinib treatment failure: Analysis from a prospective, multi-center study in China 2024 ·Annals of Oncology ·Puyuan Xing, Dongqing Lv, Weineng Feng, Shuyu Liu, Yan Yu, Jieyun Yin, Xiubao Ren, John H. Zhang, Guang Han, Yong Zhang, Shundong Cang, (unknown), En Chen, Meng Li, (unknown)	0
3	A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091). 2024 ·Journal of Clinical Oncology ·Hui Liu, Bo Qiu, Yuanyuan Zhao, Wenzhuo He, Weineng Feng, (unknown), Jun Jia, Fanjun Meng, (unknown), (unknown), JinYu Guo, (unknown), Suping Guo, (unknown), (unknown), Jibin Li, Yunpeng Yang, Liangping Xia, (unknown)	3
4	Inhibitor of apoptosis proteins (IAP) inhibitor APG-1387 monotherapy or in combination with programmed cell death 1 (PD-1) inhibitor toripalimab in patients with advanced solid tumors: results from two phase I trials 2024 ·ESMO Open ·Fangfang Liu, Xiaoli Wei, Weineng Feng, Hu Zhao, Yanhui Zhang, Zhi‐Qiang Wang, Dan Zhang, (unknown), Sijin Yang, Wentao Pan, Xiaohe Tian, (unknown), (unknown), Edison Liang, Chunlei Wang, Dawei Yang, Yuting Zhai, Miao‐Zhen Qiu, Rui‐Hua Xu	1
5	Immunotherapy in resectable NSCLC: Answering the question or questioning the answer? 2024 ·Cancer Cell ·Si‐Yang Liu, Weineng Feng, Yi‐Long Wu	7
6	Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non–Small Cell Lung Cancer 2023 ·Cancer Research ·Ziyou Lin, (unknown), Jian Zhang, Weineng Feng, Jiaye Lu, (unknown), (unknown), Shumin Ouyang, Jin‐Jian Lu, Peibin Yue, Guohui Wan, Peiqing Liu, Xiaolei Zhang	75
7	Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer 2023 ·Cancer Letters ·Jiaye Lu, (unknown), Jingwei Li, Ziyou Lin, Huaxuan Li, Linlin Lou, Wen Ding, Shumin Ouyang, (unknown), (unknown), Xiaobing Chen, Peibin Yue, Yuanxiang Wang, Peiqing Liu, (unknown), (unknown), Jian Zhang, Weineng Feng, Xiaolei Zhang	57
8	Cytotoxic pyridine alkaloids from a marine-derived fungus Arthrinium arundinis exhibiting apoptosis-inducing activities against small cell lung cancer 2023 ·Phytochemistry ·Yiwei Hu, Shuai Ma, Xiaoyan Pang, (unknown), Qianqian Liu, Fanghai Han, Junjian Wang, (unknown), Weineng Feng, Yonghong Liu, (unknown), (unknown)	8
9	Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer 2023 ·Lung Cancer ·(unknown), (unknown), Weineng Feng, Zihao Chen, Junwei Su, Hua‐Jun Chen, Wenxian Wang, Shirong Zhang, Qian Wang, Zexin Chen, Wen‐Zhao Zhong, C. Xu, Jin‐Ji Yang	11
10	First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report 2023 ·World Journal of Surgical Oncology ·(unknown), Weineng Feng, Yanming Deng, (unknown)	3
11	Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non–Small Cell Lung Cancer in Patients With Brain Metastases 2023 ·JAMA Network Open ·Xue Hou, Meichen Li, Guowu Wu, Weineng Feng, (unknown), Honghua Jiang, (unknown), Jing Chen, (unknown), (unknown), Qing Liu, Likun Chen	23
12	Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with high‐dose cisplatin 2022 ·Cancer Communications ·Yuanyuan Zhao, Bing Zhao, Gang Chen, (unknown), Zijun Liao, Haiming Zhang, Weineng Feng, Yinyin Li, Heng Weng, Weidong Li, Yuefen Zhou, (unknown), (unknown), Jianhua Chen, Zhenteng Liu, Zhenzhong Su, Wenliang Wang, Li Zhang	4
13	Therapeutic targeting RORγ with natural product N-hydroxyapiosporamide for small cell lung cancer by reprogramming neuroendocrine fate 2022 ·Pharmacological Research ·(unknown), Yiwei Hu, Jian Zhang, Qianyu Wang, (unknown), (unknown), Qianqian Wang, (unknown), Hong Wang, Tian‐Miao Ou, Weineng Feng, Peiqing Liu, Yonghong Liu, Junfeng Wang, Jie Huang, Junjian Wang	17
14	Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion 2022 ·Frontiers in Oncology ·(unknown), (unknown), Yanming Deng, Lijie Guo, Qingqing He, Tingting He, Weineng Feng	8
15	Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open-label, single-arm, phase Ib clinical trial. 2022 ·Journal of Clinical Oncology ·Zhigang Liu, Xiaotao Huang, Jun Liang, (unknown), Ye Liu, Lizhong Liang, Haiyu Hong, Weineng Feng, (unknown), Yaqin Zhang, (unknown), (unknown), Yuling Zhou, Zhaoyuan Zhang	0
16	912MO A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study 2020 ·Annals of Oncology ·(unknown), Yun Yang, (unknown), (unknown), Jianji Pan, (unknown), Lizhu Lin, Ying Shi, Weineng Feng, Jianping Xiong, Kunyu Yang, Yu Qin, Desheng Hu, Yan Sun, (unknown), Guoqing Hu, (unknown), (unknown), Qing Yang, (unknown)	5
17	270MO A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study 2020 ·Annals of Oncology ·(unknown), Yun Yang, (unknown), (unknown), Jianji Pan, (unknown), Lizhu Lin, Ying Shi, Weineng Feng, Jianping Xiong, Kunyu Yang, Yu Qin, Desheng Hu, Yan Sun, (unknown), Guoqing Hu, (unknown), (unknown), Qing Yang, (unknown)	1
18	Molecular gene mutation profiles, TMB and the impact of prognosis in Caucasians and east Asian patients with lung adenocarcinoma 2020 ·Translational Lung Cancer Research ·(unknown), Na Wang, Weiguang Gu, Yuan Qiu, Hua Zhang, (unknown), (unknown), Liheng Ma, Weijing Cai, Weineng Feng, Likun Chen	9
19	Comparison of the SuperARMS and Droplet Digital PCR for Detecting EGFR Mutation in ctDNA From NSCLC Patients 2018 ·Translational Oncology ·Weineng Feng, (unknown), Ning Zhao, (unknown), Wei Luo, Hua Zhang, (unknown), Jie Yang, Yanming Deng	32
20	Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial 2014 ·Annals of Oncology ·Qing Zhou, Ying Cheng, Jin‐Ji Yang, Mingfang Zhao, (unknown), (unknown), Zhendong Chen, Hong‐Hong Yan, Yong Song, Juxiang Chen, Weineng Feng, Chong‐Rui Xu, Z. Wang, (unknown), Wen‐Zhao Zhong, (unknown), Yi‐Long Wu	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact